Abstract | Elevated heart rate is known to induce myocardial ischaemia in patients with coronary artery disease (CAD), and heart rate reduction is a recognized strategy to prevent ischaemic episodes. In addition, clinical evidence shows that slowing the heart rate reduces the symptoms of angina by improving microcirculation and coronary flow. Elevated heart rate is an established risk factor for cardiovascular events in patients with CAD and in those with chronic heart failure (HF). Accordingly, reducing heart rate improves prognosis in patients with HF, as demonstrated in SHIFT. By contrast, data from SIGNIFY indicate that heart rate is not a modifiable risk factor in patients with CAD who do not also have HF. Heart rate is also an important determinant of cardiac arrhythmias; low heart rate can be associated with atrial fibrillation, and high heart rate after exercise can be associated with sudden cardiac death. In this Review, we critically assess these clinical findings, and propose hypotheses for the variable effect of heart rate reduction in cardiovascular disease.
In 2011, when our Review on the role of heart rate in coronary artery disease (CAD)was published 1 , the effect of heart rate over the whole spectrum of cardio vascular disease was receiving new recognition. The impetus was the 2005 approval in Europe of the specific heartratelowering agent ivabradine for patients with angina 2 . Ivabradine -in contrast to other drugs widely used for the treatment of CAD, such as βblockers and nondihydropyridine calciumchannel blockers -has no direct effect on the cardiovascular system other than heart rate reduction. In addition to its use in the clinical setting, ivabradine captured the interest of the scientific community as a tool to investigate the epidemiological, pathophysiological, and clinical role of heart rate in cardio vascular disease.
The information available in 2011 allowed us to define the negative effects of increased heart rate on both myocardial oxygen consumption and arterial stiffness, as well as to suggest that elevated heart rate can cause cardiac arrhythmias and negatively influence coronary artery shear stress 1, [3] [4] [5] [6] [7] [8] [9] . This observation naturally led to the hypothesis of an association between increased heart rate and the development and instability of athero sclerotic plaque 1 . On the basis of preclinical data from animals and humans 1, 3, 5 and the results of a prespecified subgroup of the BEAUTIFUL trial 10 , we anticipated that reducing heart rate in patients with CAD would improve their prognosis. Equally, on the basis of epidemiologi cal studies that showed an interaction between elevated heart rate and cardiac events in patients with CAD [11] [12] [13] , the scientific community started to consider elevated heart rate as a modifiable risk factor for cardiovascular events and mortality in this population.
Over the past 5 years, however, new information has become available that has allowed us to clarify some of the hypotheses we postulated in 2011 and to clarify the role of heart rate in cardiovascular disease. In addition to new experimental data [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , the results of SIGNIFY 27 have greatly contributed to our understanding of the role of heart rate in CAD. In this Review, we critically analyse these new findings, following the phases of the ivabradine development programme that encompass the effect of heartratelowering in cardiovascular dis ease. Whenever new experimental data are relevant to the clinical results, we report these in detail. Otherwise, we refer to our 2011 Review 1 .
Heart rate reduction and angina Increased heart rate can provoke myocardial ischae mia in patients with CAD. This wellestablished mech anism is the basis -at least in part -of the antianginal effect of βblockers (such as metoprolol and bisoprolol) and calciumchannel blockers (such as verapamil and diltiazem) that lower heart rate. Both of these classes of drugs, however, exert effects other than heart rate reduction that can contribute to their antiischaemic and antianginal actions. Notably, βblockers lower blood pressure, and calciumchannel blockers cause dilatation of the coronary arteries. The development programme for ivabradine in angina included a variety of studies in 1 which >6,000 patients were enrolled, and allowed the role of pure heart rate reduction in angina to be estab lished [28] [29] [30] . In all the studies, exercise test parameters improved and the number of angina attacks decreased, confirming that selective heart rate reduction prevents or attenuates the short period of myocardial ischaemia that causes angina [28] [29] [30] . In 2014, this finding was confirmed by the results of SIGNIFY 27, 31 . In patients with angina (Canadian Cardiovascular Society class ≥II), heart rate reduction with ivabradine resulted in a reduction in angina class at 3 months 27 , and in an improvement in quality of life at 12 months 31 . Classically, the antianginal effect of heartrate lowering is explained in terms of reduction of myo cardial oxygen consumption, and increased time available for coronary perfusion, which occurs predominantly during diastole 32 . The interaction between heart rate and myo cardial perfusion in the presence of substantial coronary stenosis is, however, more complex. A description was presented in our 2011 Review 1 , including the role of the 'collateral steal' phenomenon (due to a redistribution of flow away from poststenotic myocardium) 33 ; the possi bility of 'paradoxical vasoconstriction' induced by acute heart rate increase 34, 35 ; and the 'accelerated deterior ation' of the vessel elastin fibres, with fraying, fragmen tation, and functional deterioration leading to increased arterial stiffness 36, 37 . In the past 5 years, new information has become avail able, and our understanding of the interaction between heart rate and myocardial perfusion in CAD has been refined. In one study, a murine model of hindlimb col lateral arteriogenesis was used to test the effects of heart rate reduction by I f channel inhibition with ivabradine versus that with adrenergic βreceptor blockade with metoprolol 14 . The hypothesis was that collateral arter ies protect from ischaemia and that heart rate reduc tion could improve arteriogenesis and perfusion, thus reducing ischaemia and, eventually, vascular events. The researchers demonstrated that heart rate reduction with ivabradine, but not with metoprolol, stimulated adaptive collateral artery growth only in dyslipidaemic apolipo protein E-deficient mice, not in wild types 14 . The molecular mechanism is likely to be improved endothelial function, as shown by upregulation of endothelial nitric oxide synthase expression and activity, as well as down regulation of gene expression of classical inflammatory cytokines (IL6, tumour necrosis factor, and transforming growth factor β) and the angiotensin II receptor type 1.
The clinical relevance to the coronary arteries of these experimental findings was subsequently evalu ated in a singleblind study of 46 patients with CAD, who were randomly allocated to ivabradine or placebo 15 . The primary outcome was collateral flow index, measured invasively during a 1min coronary artery balloon occlusion at baseline, and repeated at 6month follow up. Ivabradine significantly increased collateral flow index, suggesting a proarteriogenic effect of heart rate reduction in patients with CAD. Of course, these data have only proofofconcept value but, if confirmed, could provide an additional explanation for the sympto matic effect of heart rate reduction in angina 16 . In an elegant study of 21 patients with CAD, heart rate reduc tion with ivabradine reduced resting coronary blood flow and increased hyperaemic coronary flow, leading to a net improvement in coronary flow reserve, which remained improved after restoration of baseline heart rate with pacing 38 . A 2015 study of patients with angina supported these data and showed the superiority of pure heart rate reduction with ivabradine to enhance coro nary flow reserve over that achieved with the βblocker bisoprolol 17 . Taken together, these data indicate that slowing heart rate improves microcirculation and coro nary flow reserve, probably as a result of enhanced ventricular diastolic relaxation time, which is more pronounced with ivabradine than with βblockade 39, 40 .
These new experimental and clinical data confirm that reducing heart rate improves the symptoms of angina, and expand our knowledge of the mechanisms involved (FIG. 1) . Heart rate is an important regulator of oxygen consumption by mitochondrial oxidation of the myocytes, and its reduction increases the ischaemic threshold and maintains myocyte viability. In addition, the effect of heart rate reduction at the level of the coro nary arteries can stimulate arteriogenesis and improve coronary flow reserve. These beneficial effects on coro nary arteries could help to prevent micro vascular angina and, theoretically, contribute to reducing cardiovascular events.
Heart rate and clinical outcome in CAD In our 2011 Review, we hypothesized that elevated rest ing heart rate in patients with CAD was a modifiable risk factor for cardiovascular events and mortality 1 . We also discussed the adverse effects of elevated heart rate on the balance between antiatherogenic and pro atherogenic genes, by modulating the ratio between detri mental oscillatory shear stress (during systole), and protective unidirectional, high shear stress (during dias tole) 1 . Finally, we speculated that, in the presence of risk factors such as smoking, hyperlipidaemia, and hyper glycaemia, elevated heart rate results in endothelial oxidative stress, inflammation, and increased throm bogenicity favouring progression of atherosclerosis, plaque rupture and, eventually, adverse outcomes 1 . This biological hypothesis was supported by a large amount of clinical data. Epidemiological studies and sub studies of large clinical trials have consistently shown that elevated heart rate is associated with increased mortality and rates of cardiac events in patients with
Key points
• The role of heart rate in coronary artery disease and heart failure has been explored using ivabradine, a drug that selectively targets heart rate • Increased heart rate can provoke myocardial ischaemia • Heart rate reduction can reduce the symptoms of angina • Increased heart rate is a risk marker in patients with coronary artery disease, but heart rate reduction does not improve prognosis in this clinical setting • In the setting of heart failure, elevated heart rate is a modifiable risk factor -reducing heart rate improves prognosis in these patients • Excessive bradycardia can cause dispersion of atrial fibrillation 1, 12, 13, 40 . In BEAUTIFUL 10, 11 , the relative risk of cardiovascular death was increased by 34% in patients receiving placebo who had a heart rate ≥70 bpm compared with those with a heart rate <70 bpm, and the rate of cardiovascular death increased progressively with baseline heart rate. Moreover, in a post-hoc analy sis of patients with lifelimiting angina and heart rate ≥70 bpm, reducing heart rate with ivabra dine was associ ated with significant 73% and 59% risk reductions for myocardial infarction (MI) and coro nary revascularization, respectively 41 . In view of these data, to hypothesize that selective heart rate reduction would lead to an improvement in outcomes in patients with CAD was reasonable.
The objective in SIGNIFY 27 was to put this theory to the test. Enrolled patients (n = 19,102) had stable CAD and additional cardiovascular risk factors, a resting heart rate ≥70 bpm, with no symptoms of HF or left ventricu lar systolic dysfunction (left ventricular ejection frac tion [LVEF] at baseline: 56.5 ± 8.6%), and were receiving guidelinebased background therapy. Contrary to the study hypothesis, heart rate reduction with ivabradine had no effect on the primary end point -a compos ite of cardiovascular death and nonfatal MI -with an event rate of 6.8% for ivabradine and 6.4% for placebo (median followup 27.8 months; HR 1.08, 95% CI 0.96-1.20, P = 0.20) 27 . No significant difference between the groups was observed in terms of any second ary end points including cardiovascular death, nonfatal MI, or allcause death. SIGNIFY 27 unequivocally showed that pure heart rate reduction does not prevent cardio vascular death or MI in patients with CAD who have no clinical signs of HF and so, evidently, does not slow the progression of atherosclerosis or prevent plaque rupture leading to MI. The study also showed that, in patients with CAD and no left ventricular dysfunction or overt HF, increased heart rate is not a modi fiable risk factor, but only a marker of other processes that influence the progression of CAD (for example, hyperlipidaemia, diabetes mellitus, or smoking) 27 . The question now is, how do we explain the unexpected and counterintuitive results of SIGNIFY 27, 31 ? Indeed, the findings contrast with those from SHIFT 42 , in which improved outcomes were reported for patients with systolic HF who received ivabradine. Therefore, the data from SIGNIFY 27,31 cannot be interpreted with out first discussing the role of elevated heart rate in patients with HF.
Heart rate and clinical outcome in HF The role and relevance of increased heart rate in patients with HF is more complex than in those with CAD 43 . In the setting of HF, heart rate reflects the degree of neuroendocrine stimulation (that is, activation of the sympathetic nervous system and renin-angiotensin system), which is known to be beneficial in the short term, but detrimental in the long term 44 . The elevation of heart rate increases stroke volume, which is consid ered to be a compensatory mechanism 45 . However, pro longed neuroendocrine activation resulting in depletion of catecholamines in failing myocytes, as first described in 1966 (REF. 46 ), also has negative effects on the heart. Excess circulating catecholamines have a direct deleteri ous effect on the myocytes, leading to hypertrophy and apoptotic death which, in turn, cause left ventricular remodelling 47 . Remodelling is another complex, and not fully understood, phenomenon in which the ventricle progressively enlarges, with a reduction in LVEF. Heart rate reduction with βblockers is known to improve the outcome of patients with HF, partly by reducing -and even reversing -the progression of left ven tricular remodelling, as demonstrated by the increase in LVEF with chronic βblockade 48 . Paradoxically, there fore, longterm βblockade in the setting of HF exerts positive inotropism, despite the wellknown negative inotropic action of this class of drugs 49, 50 . Whether pos itive inotropism is the result of heart rate reduction, or other actions mediated by βadrenergic receptor blockade such as prevention of the detrimental effects of catecholamines on the myocytes, is difficult to establish.
The results of SHIFT 42 improved our understanding of the role of heart rate in HF; elevated heart rate has now been established as an independent risk marker and a prognostic risk factor in patients with HF. SHIFT 42 included 6,558 patients in sinus rhythm with stable symptomatic chronic HF, LVEF <35%, and a resting heart rate ≥70 bpm. The aetiology of HF was ischaemic in 68% of patients and nonischaemic in 32%. Patients were randomly assigned to ivabradine or placebo, and received optimal guidelinedriven standard treatment for HF. Notably, 89% of participants were already tak ing βblockers at the maximumtolerated dose. The pri mary composite end point of cardiovascular death or hospital admission for worsening HF was significantly reduced by 18% in the ivabradine group (P <0.0001), largely driven by a reduction in HF death and hospital ization for HF, which were reduced by 26% (P = 0.014) and 26% (P <0.0001), respectively 42 . A further analysis of the results from SHIFT 51 showed that the higher the heart rate at baseline, the worse the outcome. This finding suggests that heart rate is a marker of the severity of HF. Moreover, in SHIFT 51 , the greater the heart rate reduction achieved with ivabradine, the lower the mortality. This result Figure 1 | Beneficial effects of heart rate reduction in angina. Heart rate reduction decreases oxygen consumption in the myocyte and, in so doing, maintains viability. In addition, heart rate reduction prolongs diastolic perfusion time and improves coronary flow reserve. Both these effects on the myocyte and coronary arteries increase the ischaemic threshold, which results in less angina. shows that the marker is also a risk factor, meaning that the increase in heart rate itself has pathological effects including deterioration of left ventricular function, which, in turn, increases neuroendocrine activation creating a vicious cycle of decline. Therefore, a heart rate ≥70 bpm actively contributes to adverse outcome in patients with HF, and should be reduced with therapy. This phenomenon of 'tachycardiamediated cardio myopathy' is not new, and has been reported in several animal models and clinical studies 52, 53 . Trials of patients with HF who have implanted pacemakers have demon strated that heart rate per se affects left ventricular func tion; increasing the rate of pacing leads to increases in left ventricular systolic and diastolic volumes and reduction of LVEF 54, 55 . The benefits of slowing the heart rate in patients with HF are likely to be the result of a combination of factors (FIG. 2) . Firstly, the relationship between force and frequency, by which the heart regulates cardiac function, is altered in patients with HF. The force of healthy papillary muscle increases proportionally to the increase in heart rate. By contrast, the force developed by papillary muscle in the presence of HF becomes neg ative and decreases in response to the same increment of heart rate 56, 57 . As a result, in HF, the compensatory mechanism of heart rate is not only lost, but actually reversed -increasing heart rate coincides with a reduction in contractility and negative inotropism, and vice versa 45, 58 . Secondly, the pressure-volume relation ship is also altered in HF, leading to an increased after load 59 . Arterial stiffness is increased in the setting of HF, whereas arterial compliance and elasticity, which rep resent resistant and pulsatile afterload to the heart, are reduced. Selective heart rate reduction has been shown, in both animals and humans, to improve total arterial compliance and effective arterial elasticity, thereby unloading the ventricle and improving remodel ling 18, 19, 59 . In animals, however, this effect is not achieved by heart rate reduction with metoprolol 60 . Thirdly, high heart rate increases myocardial energy requirement and often induces local hypoxia, which stimulates the pro duction of cytokines, free radicals, and vasoconstric tors implicated in the development of left ventricular remodelling 47 . Heart rate reduction decreases energy expenditure, as shown by higher energy phosphate availability, and improves cardiac metabolism and remodelling in experimental models 61, 62 . As in the experimental setting, the progression of left ventricular remodelling was significantly reversed by reducing heart rate with ivabradine in both BEAUTIFUL 63 and SHIFT 64 . In line with the clinical results, new experimental data show that remodelling is specifically attenuated by selective heart rate reduction with ivabradine. In a model of angiotensin IIinduced HF in mice, ivabradine, but not metoprolol, improved systolic and diastolic left ventricular function, despite a similar reduction in heart rate with each drug 20 . Angiotensin II infusion induced upregulation of sev eral proinflammatory cytokines, levels of which were reduced to values similar to those in control animals by both ivabradine and metoprolol 20 . Therefore, the different effects of ivabradine and metoprolol cannot be explained by different effects on inflammation. Ivabradine, but not metoprolol, attenuated the upregu lation of the mRNA of metalloproteinase and colla gen I and II, and slowed the increases in apoptosis and hypertrophy induced by angio tensin II infusion 20 . These effects are the most likely explanation for the different effects of the two drugs.
Hypertrophy and apoptosis are two wellregulated and opposite processes, one representing life and the other death 21 . Both are activated by the same triggers, such as mechanical stretch, tissue neuroendocrine acti vation, and upregulation of hyperpolarization chan nels 22 . The simultaneous presence of apoptosis and hypertrophy in the failing heart has been suggested to be the result of a shift from the adult to embryonic genetic programme of the myocyte, resulting in embry onic phenot ypes in which the life and death cycle is present and active 47 . Interestingly, the I f hyperpolar ization channels, which are the target for ivabradine, might be involved in (and could even be the cause of) the shift to the embryonic programme through changes in Notch signalling, the system that ultimately decides the fate of the cell 22 . In addition, the I f current and hyperpolarization activated cyclic nucleotidegated Figure 2 | Beneficial effects of heart rate reduction in heart failure. Heart rate reduction improves the relationship between force and frequency at the level of failing myocytes, with consequent positive inotropism. Heart rate reduction also results in unloading of the ventricle and improves the ventricular pressure-volume curve which, with a decrease in energy expenditure, results in reduced or reversed left ventricular remodelling.
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Failing myocyte channel (HCN) isoform have been shown to be upregu lated in atrial and ventricular myocytes from rats and humans with severe HF [65] [66] [67] . These electrophysio logical alterations in nonpacemaker cells resemble the embryonic programme, because the embryonic heart expresses hyperpolarization channels and I f current 68 . In rats with postinfarction left ventricular remodelling, longterm ivabradine treatment reversed electrophysio logical and haemodynamic remodelling through a decrease in functional and molecular overexpression of HCN in ventricular and atrial cardiomyocytes through transcriptional and posttranscriptional effects [69] [70] [71] (FIG. 3) . Whether overexpression of the I f current in non pacemaker cells in individuals with HF contributes to remodelling and to adverse outcomes is uncertain and difficult to establish. What is certain, however, is that none of these alterations occurs in the healthy ventricle, as in the patients enrolled in SIGNIFY 27, 31 .
Explaining the results of SIGNIFY
The results of SIGNIFY 27, 31 came as a surprise to the scientific community; reducing heart rate was widely believed to provide cardiac protection, particularly in patients with CAD. A substantial body of experimen tal data supported the notion that heart rate reduction produces direct benefit on myocytes by saving energy, and indirect benefit on the coronary arteries by limiting the development of atherosclerotic plaque, resulting in improved myocardial perfusion 5, 14, 16, 34, 35, 38 . In a pig model of ischaemiainduced ventricular fibrillation, ivabra dine provided cardioprotection by increasing regional myocardial blood flow, preserving cardiomyocyte via bility, mitochondrial structure, Ca 2+ homeostasis, and energy status, and limiting formation of reactive oxygen free radicals 72, 73 . The cardioprotective effects of ivabra dine were also demonstrated in rodent models 23, 74, 75 .
However, no cardioprotection was observed when heart rate was reduced by propranolol, suggesting a pos sible pleiotropic action of ivabradine, beyond heart rate reduction 72, 76 . Evidence of ivabradineinduced cardio protection through a beneficial effect on the arteries in mice was originally shown in 2008 by Custodis et al. 5, 33, 77 . The results were replicated by other groups, extending to several animal models with different arterial sys tems and settings of endothelial dysfunction [24] [25] [26] 78, 79 . Nevertheless, as with other promising drugs whose experimental cardio protective effects did not translate to humans, ivabra dine did not improve the outcomes of patients with CAD in SIGNIFY 27, 31, 80 . A full account of the complex mechanisms behind the lack of benefit for ivabradine in SIGNIFY are beyond the scope of this Review. Briefly, differences in ischaemic duration, residual blood flow, and coronary perfusion territory could contribute to this lack of translation in benefits between animals and humans. Moreover, the complex and longlasting pathophysiology of CAD, and the use of concomitant treatments in humans are difficult to reproduce in animal models. The results of SIGNIFY 27, 31 emphasize the importance of testing hypotheses derived from experi mental studies and subgroup analyses in welldesigned clinical trials.
The question remains as to why ivabradine improved the prognosis of patients with HF in SHIFT 42 , but not those with CAD in SIGNIFY 27, 31 . At least two possible explanations, which are not mutually exclusive, have been proposed 81, 82 . The first explanation is based on the results of BEAUTIFUL 10 and SHIFT 42 ; the patient populations of these trials overlap in many aspects, except for the aetiology of left ventricular dysfunction 81 . Investigators estimated that approximately onethird of the SHIFT study population had HF of nonischaemic origin 42 , and heart rate reduction with ivabradine pro duced the best outcome in this subgroup of patients 42, 81 . Ivabradine significantly reduced the primary compos ite outcome both in patients with nonischaemic HF (HR 0.72, 95% CI 0.60-0.85) and in those with ischae mic HF (HR 0.87, 95% CI 0.78-0.97) 42 . In patients with CAD and left ventricular dysfunction in BEAUTIFUL 11 , ivabradine had no effect on the composite end point of cardiovascular death or HF hospitalization, or either of its components, in the subgroup with heart rate ≥70 bpm. Ivabradine did reduce the incidence of the secondary end points -admission to hospital for fatal and nonfatal MI (HR 0.64, 95% CI 0.49-0.84) and coro nary revascularization (HR 0.70, 95% CI 0.52-0.93) 11 . One possible biological explanation for these data is that, in patients with ischaemic left ventricular dysfunction, the loss of myocytes resulting from infarction leaves too little surviving myocardium for meaningful improve ment. However, in nonischaemic left ventricular dys function, more viable myocardial tissue is available and could contribute to improvement in cardiac function. The patients enrolled in SIGNIFY 42 had preserved LVEF, leaving no room for improvement in cardiac function. Similarly, digoxin and some βblockers have been shown to have differential effects on outcome depending on the underlying aetiology in patients with HF [83] [84] [85] . Figure 3 | Molecular explanation for the effects of ivabradine independent of heart rate reduction. In heart failure, ivabradine might have effects other than heart rate reduction. Containment of ventricular overexpression of the I f channel leads to reduced apoptosis and hypertrophy, as well as electrophysiological remodelling. HCN, hyperpolarization-activated cyclic nucleotide-gated channel.
The second explanation for the opposing results observed in SHIFT 27, 31 and SIGNIFY 42 is that elevated heart rate is an important risk factor, but only when left ventricular function is reduced 82 . In SIGNIFY, elevated heart rate was hypothesized to have exerted a deleterious effect only on the progression of coro nary artery atherosclerosis. However, the results do not support this theory, because ivabradine had no effect on the incidence of cardiovascular death or MI 27 . This finding questions whether an increase in heart rate in the absence of left ventricular dysfunction is a risk fac tor, an epiphenomenon of the underlying pathological process, or simply a physiological response. Regardless, in patients with CAD, unlike those with HF, elevated heart rate is not an index of neuroendocrine activation.
The results of BEAUTIFUL 10 seem to go against the second hypothesis (that the benefit of heart rate reduction depends on left ventricular function). In the subgroup of patients with elevated heart rate and left ventricular dysfunction, ivabradine did not reduce the incidence of the primary end point or hospital ization for HF, despite having effects on left ventricu lar remodel ling that were similar to those in SHIFT 63 . Conversely, a subgroup analysis from SHIFT 86 seems to contradict the first hypothesis (that the effect of heart rate depends on the aetiology of left ventricular dys function). In the subgroup of patients of SHIFT who had angina (and probably CAD), ivabradine improved prognosis, with results similar to those observed in the subgroup of patients with angina in BEAUTIFUL 41 . Notably, these data come from post hoc, not pre specified, subgroup analyses, raising the possibility of invalid results. Moreover, BEAUTIFUL is a neutral study for which, from a purely statistical point of view, subgroup analyses have little or no validity and should not even be considered. However, for every large trial, a temptation -if not a duty -exists to analyse the data extensively in the hope of finding plausible explanations for the results.
In stable CAD, elevated heart rate is a well established determinant of ischaemia, and its reduction is a recognized strategy to prevent ischaemic episodes and the symptoms of angina. Accordingly, ivabradine had symptomatic benefits in SIGNIFY 27 , despite the lack of prognostic benefit. In SIGNIFY 27 , patients with lifelimiting angina seemed to have worse outcomes with ivabradine than with placebo. An explanation for this finding has not been forthcoming, and some con cern about a potential harmful effect of ivabradine in this subgroup has arisen in the medical community. However, the regulatory authorities maintained the benefit-risk ratio of ivabradine as a treatment to relieve the symptoms of angina 87 .
Implications for β-blocker therapy
The discovery that reducing heart rate in patients with CAD does not affect prognosis came as a surprise, because βblockers are widely thought of as the first line therapy in these patients 88 . This supposition is based on the potent antianginal effects of βblockers, as well as extrapolation of the prognostic benefit demonstrated in patients who have experienced an MI 89 and in those with HF 90 . However, the studies sup porting the efficacy of βblockers in patients with CAD but without HF were performed before the current era; that is, before use of coronary revascularization and contemporary medical therapy with antiplatelet drugs, statins, and angiotensinconverting enzyme (ACE) inhibitors 88 . The same is true for studies of calcium channel blockers, such as verapamil and diltiazem, that also reduce heart rate 91, 92 . To suppose that the CAD phenotype has changed over the years is not unreason able. A reperfused myocardium is less arrhythmogenic, and its function is less affected by timely revasculariza tion than necrotic, scarred muscle. Many of the agents in common current use (that were background ther apy in SIGNIFY 27 ), such as aspirin, statins, and ACE inhibitors, exert beneficial effects on the coronary artery endothelium, with reduction in atherosclerosis progression and plaque stabilization 88 . Analysis of data from contemporary registries suggests that, in daily clinical practice, βblockers do not improve the prognosis of patients, irrespective of whether they have had an MI 93, 94 . This evidence, how ever, comes from observational, nonprospective, ran domized clinical studies and should, therefore, be considered with caution. Accordingly, in the latest ver sion of the European (2013) 95 and US (2012) 96 guidelines, recommendations for the longterm use of βblockers have been downgraded in patients with CAD, restrict ing them for those who also have HF or left ventricular dysfunction. Controversy also surrounds the efficacy of βblockers during noncardiac surgery 97, 98 and after coro nary artery bypass graft surgery in patients with good left ventricular function 99, 100 . Current reports on βblockers are essentially retro spective analyses of prospectively collected data with multivariate adjustments and propensity matching, and βblockers could exert effects other than heart rate reduction. However, the lack of prognostic benefit for βblockers provides an additional line of evidence supporting the concept that heart rate reduction carries prognostic benefit only when the ventricle is damaged and its function is reduced.
Heart rate and cardiac arrhythmias In 2011, when our previous Review 1 was published, elevated heart rate rather than bradycardia seemed to be associated with an increased risk of supraventricular and ventricular arrhythmias, including atrial fibrilla tion (AF), especially in patients with CAD. This associ ation was demonstrated in experimental models using dogs 101 and pigs 102 , a large trial 7 , and an epidemiologi cal survey 8 . In 2016, we know that the opposite might also be true; that is, heart rate reduction can under certain circumstances be linked to AF. BEAUTIFUL 10 , SIGNIFY 27 , and SHIFT 42 all showed a trend towards a slight increase in emergent AF in the ivabradine group, which was significant in SIGNIFY 27 . Several reasons exist for such an association. Bradycardia can cause dispersion of atrial repolarization which, in turn, can initiate AF (the recognized mechanism of 103 . Interestingly, an increased risk of AF has been reported in elderly Norwegian men with a history of longterm endurance sport practice leading to bradycardia 104 . Polymorphisms of the HCN channel, the molecular subunit for I f , are associated with asymptomatic sinus bradycardia, sinus arrhyth mia, and AF 105 . Moreover, in disease states such as HF, HCN channels are not restricted to the sinus node, and are expressed in a large portion of the myocardium 66 . However, inhibition of I f by ivabradine could also be beneficial in AF, as demonstrated by a reduction in the spontaneous activity of cardiomyocytes in the pul monary vein of rabbits 79 . Whether the findings from this rabbit model can be extrapolated to humans is uncertain, particularly when the data were obtained using a concentration of ivabradine much higher than that used clinically or in SIGNIFY 105 . In SIGNIFY 106 , the incidence of emergent brady cardia was higher than in the other ivabradine trials, because of the higher dosage regimen (10 mg twice daily compared with a standard dose of 5.0 mg or 7.5 mg twice daily). Treatment with ivabradine also increased the rate of AF events, the majority of which were paroxysmal, by 0.7% per year. Although -as would be expected -the outcome in patients who developed AF was worse than those who did not, in SIGNIFY 106 , neither bradycardia nor AF affected study outcomes. The safety of heart rate reduction with ivabradine in patients with congenital or acquired long QT syndromes, who were excluded from the ivabradine trials, has been a subject of debate [107] [108] [109] [110] .
Although ivabradine does not seem to increase heart ratecorrected QT interval 111 , in the absence of speci fic studies of patients with congenital or acquired long QT syndromes, ivabradine should be avoided in these individuals.
Conclusions
Heart rate is no longer a forgotten link in CAD 1 . In just 5 years, our knowledge of the role of heart rate in cardio vascular disease has greatly improved. When left ventricular function is maintained, increased heart rate seems to be a marker of processes that might influ ence the progression of atherosclerosis towards serious and irreversible damage in the coronary arteries, such as MI. In these early stages of cardiovascular disease, reducing heart rate is not beneficial in terms of redu cing the progression of atherosclerosis in the coronary arteries. Therefore, contrary to popular belief, reducing heart rate does not have a prognostic effect in these patients. However, in the presence of coronary plaque or a defect in coronary microcirculation, a further shortterm increase in heart rate (such as during exer cise or with emotion) is a determinant of ischaemia. In this case, heart rate reduction is relevant to enhance the ischaemic threshold of hypoperfused myocytes and prevent angina (FIG. 4) . Consequently, agents with negative chronotropic capacities -such as βblockers, nondihydropyridine calciumchannel blockers, and ivabradine -are indicated to reduce the symptoms of angina. To improve prognosis, antiplatelet agents, statins, and ACE inhibitors, which act on recognized CAD risk factors, are required.
With the progression of CAD resulting in MI, left ventricular dysfunction and, eventually, HF, the role of increased heart rate changes. When left ventricular function is already impaired, increased heart rate itself contributes to left ventricular deterioration. Under these circumstances, heart rate is both a marker of the progression of CAD and a determinant of adverse prognosis, and heart rate reduction has been proven to improve prognosis (FIG. 4) . For this reason, βblockers are indicated as firstline treatment to reduce mortal ity in patients with HF. Reduction of heart rate with ivabradine further to that achieved with βblockers has been recognized in the ESC guidelines for the diagnosis and treatment of HF 112 as useful to improve outcome, confirming the prognostic benefit of pure heart rate reduction in HF. Interestingly, the negative chrono tropic effect of ivabradine in addition to βblocker therapy could be linked to specific actions of the drug on the overexpressed I f channel in the failing heart.
Undoubtedly, the availability of a research tool such as ivabradine has added a great deal to our knowledge of the role of heart rate in CAD. Discrepancies between experimental and clinical data still exist and merit fur ther exploration. Equally, deeper evaluation of the results from registries and clinical trials are expected to lead to a better understanding of the interaction between heart rate and left ventricular function in set tings other than CAD. This is the beauty of medicine -our knowledge changes as science progresses. During the early phase of cardiovascular disease, before structural changes in the heart (infarction) occur, increased heart rate is a marker of coronary artery disease suggesting progression of pathology. Reduction of heart rate under these circumstances does not improve prognosis, but can reduce the symptoms (angina) of the underlying disease. However, in the setting of reduced ventricular function, an increase in heart rate is not only a marker, but also a risk factor and contributes to the progression of left ventricular remodelling. In patients with heart failure, therefore, heart rate reduction is associated with improved prognosis.
